A-CAR032

N/A

Report date: 2026/01/16 20:01:23

Base Information

Drug NameA-CAR032
Drug Alias NameA-CAR032
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionSix-transmembrane epithelial antigen of the prostate 2 modulatorsT lymphocyte replacements
TargetsSix-transmembrane epithelial antigen of the prostate 2
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCellular Biomedicine (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCellular Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A